Publications and Presentations Database
Adopting genetics: motivations and outcomes of personal genomic testing in adult adoptees..
Genetics in medicine : official journal of the American College of Medical Genetics. 18(9), 924-32. Abstract
(2016).
Age-group differences in treatment outcomes for male veterans with severe schizophrenia: a three-year longitudinal study.
Journal of geriatric psychiatry and neurology. 13(2), 78-86. Abstract
(2000).
Amyloid imaging, risk disclosure and Alzheimer’s disease: ethical and practical issues.
Neurodegenerative disease management. 3(3), 219 - 229.
(2013).
Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives.
The gerontologist. 40(1), 43-52. Abstract
(2000).
APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts..
PLoS medicine. 14(3), e1002254. Abstract
(2017).
Associations between risk perceptions and worry about common diseases: a between- and within-subjects examination.
Psychology & Health. 28(4), 434-49. Abstract
(2013).
Associations between self-referral and health behavior responses to genetic risk information..
Genome medicine. 7(1), 10. Abstract
(2015).
Black and white adult family members' attitudes toward a dementia diagnosis.
Journal of the American geriatrics society. 57(9), 1562-8. Abstract
(2009).
Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk.
Genetics in medicine : official journal of the American College of Medical Genetics. Abstract
(2011).
Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine..
American journal of human genetics. 99(1), 246.
(2016).
Communicating mild cognitive impairment diagnoses with and without amyloid imaging..
Alzheimer's research & therapy. 9(1), 35. Abstract
(2017).
Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease.
Alzheimer's & Dementia : the journal of the Alzheimer's Association. 4(6), 406-13. Abstract
(2008).
Consumer Perceptions of Interactions With Primary Care Providers After Direct-to-Consumer Personal Genomic Testing..
Annals of internal medicine. 164(8), 513-22. Abstract
(2016).
(2014).
Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment..
Journal of Alzheimer's disease : JAD. 52(1), 17-24. Abstract
(2016).
Diet and exercise changes following direct-to-consumer personal genomic testing..
BMC medical genomics. 10(1), 24. Abstract
(2017).
Differences between African Americans and Whites in their attitudes toward genetic testing for Alzheimer's disease.
Genetic testing. 7(1), 39-44. Abstract
(2003).
Differences between African Americans and whites in their perceptions of Alzheimer disease.
Alzheimer disease and associated disorders. 17(1), 19-26. Abstract
(2003).
Direct-to-consumer genetic testing and personal genomics services: a review of recent empirical studies.
Current genetic medicine reports. 1(3), 182-200. Abstract
(2013).
Direct-to-Consumer Genetic Testing: User Motivations, Decision Making, and Perceived Utility of Results..
Public health genomics. 20(1), 36-45. Abstract
(2017).
Disclosing individual CDKN2A research results to melanoma survivors: interest, impact, and demands on researchers.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Abstract
(2011).
Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial..
Annals of internal medicine. 164(3), 155-63. Abstract
(2016).
Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease.
Journal of health communication. 14(8), 768-84. Abstract
(2009).